Recent News
-
Aspira Women’s Health, Inc. Announces First Patient Enrolled in Prospective OVANex Study for Benign Pelvic Mass Monitoring
For a pdf of this press release please click here AUSTIN, Texas — June 29, 2020 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the first patient enrolled in a national clinical study of benign pelvic mass management. The study will enroll over 1,000 women for assessing ovarian cancer…
-
Vermillion, Inc. Announces Rebranding and Company Name Change to Aspira Women’s Health Inc.
For a pdf of this press release please click here AUSTIN, Texas — June 11, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on ovarian cancer risk assessment, today announced a major rebranding to reflect the company’s continuing evolution towards becoming a comprehensive gynecologic health company, including a corporate name change…
-
Vermillion Completes Validation of New Pre-Surgical Test Offerings with OVA1®plus, including COVID-19 Antibody Testing and Additional Pelvic Mass Risk Assessment Biomarkers
For a pdf of this press release please click here AUSTIN, Texas — June 10, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its wholly-owned subsidiary ASPIRA Labs has completed laboratory validation of the Roche Elecsys Anti-SARS-CoV-2 antibody test for detecting the presence…
-
Vermillion Set to Join Russell 3000 Index
For a pdf of this press release please click here AUSTIN, Texas — June 9, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it is set to join the broad-market Russell 3000(R) Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after…
-
Vermillion Reports First Quarter 2020 Financial Results
For a link to a pdf of the press release please click here AUSTIN, Texas — May 14, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter March 31, 2020. “Despite late first quarter challenges from COVID-19, we delivered strong…